DD288094A5 - Verwendung von gamma-interferon zur behandlung von gefaessverengungen - Google Patents

Verwendung von gamma-interferon zur behandlung von gefaessverengungen Download PDF

Info

Publication number
DD288094A5
DD288094A5 DD89333072A DD33307289A DD288094A5 DD 288094 A5 DD288094 A5 DD 288094A5 DD 89333072 A DD89333072 A DD 89333072A DD 33307289 A DD33307289 A DD 33307289A DD 288094 A5 DD288094 A5 DD 288094A5
Authority
DD
German Democratic Republic
Prior art keywords
interferon
gamma
cells
treatment
smooth muscle
Prior art date
Application number
DD89333072A
Other languages
German (de)
English (en)
Inventor
Goetan Hansson
Lena Jonasson
Jan Holm
Original Assignee
Hannson Goeran
Lena Jonasson
Jan Holm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hannson Goeran, Lena Jonasson, Jan Holm filed Critical Hannson Goeran
Publication of DD288094A5 publication Critical patent/DD288094A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DD89333072A 1988-09-30 1989-09-28 Verwendung von gamma-interferon zur behandlung von gefaessverengungen DD288094A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8803472A SE462364B (sv) 1988-09-30 1988-09-30 Anvaendning av gamma-interferon foer beredning av ett preparat foer behandling av vaskulaer stenos

Publications (1)

Publication Number Publication Date
DD288094A5 true DD288094A5 (de) 1991-03-21

Family

ID=20373494

Family Applications (1)

Application Number Title Priority Date Filing Date
DD89333072A DD288094A5 (de) 1988-09-30 1989-09-28 Verwendung von gamma-interferon zur behandlung von gefaessverengungen

Country Status (18)

Country Link
US (1) US5208019A (da)
EP (1) EP0367735B1 (da)
JP (1) JP2895896B2 (da)
KR (1) KR0137017B1 (da)
AT (1) ATE86869T1 (da)
AU (1) AU623181B2 (da)
CA (1) CA1338722C (da)
DD (1) DD288094A5 (da)
DE (1) DE68905438T2 (da)
DK (1) DK174523B1 (da)
HU (1) HU206988B (da)
IE (1) IE63874B1 (da)
IL (1) IL91796A (da)
NZ (1) NZ230816A (da)
PH (1) PH26293A (da)
PT (1) PT91863B (da)
SE (1) SE462364B (da)
WO (1) WO1990003189A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2131550A1 (en) * 1992-02-05 1993-08-19 Andrew Zalewski Interferon gene therapy for the treatment of vascular disorders
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5957972A (en) * 1992-09-29 1999-09-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Implants possessing a surface of endothelial cells genetically-modified to inhibit intimal thickening
AU685080B2 (en) * 1993-01-07 1998-01-15 Thomas Jefferson University Antisense inhibition of C-MYC to modulate the proliferation of smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6323184B1 (en) 1993-10-15 2001-11-27 Thomas Jefferson University Arteriovenous and venous graft treatments: methods and compositions
US6133242A (en) * 1993-10-15 2000-10-17 Thomas Jefferson Univerisity Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes
US5449679A (en) * 1994-07-29 1995-09-12 Leonard; Robert J. Process and products for reducing biological fluid levels of a lipid soluble waste
US5665591A (en) * 1994-12-06 1997-09-09 Trustees Of Boston University Regulation of smooth muscle cell proliferation
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
ATE377418T1 (de) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
CA2210622A1 (en) * 1995-11-17 1997-05-29 Toray Industries, Inc. An agent protecting endothelial cells
US5681558A (en) * 1995-11-30 1997-10-28 Berlex Laboratories, Inc. Method of using beta-interferons to treat restenosis
ES2314786T3 (es) 1998-04-02 2009-03-16 Genentech, Inc. Uso de interferon gamma para el tratamiento de la hipertrofia cardiaca.
US7524826B2 (en) * 2000-04-14 2009-04-28 Mcmaster University And Hamilton Health Sciences Corporation Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque
WO2002089828A2 (en) * 2001-05-04 2002-11-14 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
WO2005074650A2 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU558002B2 (en) * 1981-07-14 1987-01-15 Scotia Holdings Plc Enhancement of 1 series pg production using retinol or carotenoids and linolenic acid
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US4454115A (en) * 1981-10-23 1984-06-12 Wisconsin Alumni Research Foundation Method of reducing the level of low density lipoproteins in the serum of a patient
US4483849A (en) * 1983-01-07 1984-11-20 Carter William A Stabilization and purification of interferon with propylene glycol, resulting in a non-toxic product
JPS6069037A (ja) * 1983-09-26 1985-04-19 Sunstar Inc エリテマト−デス治療用外用剤
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4946674A (en) * 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
US5026544A (en) * 1988-02-16 1991-06-25 Board Of Reagents, The University Of Texas System Methods and compositions for inhibiting the growth of neoplastic cells

Also Published As

Publication number Publication date
SE8803472D0 (sv) 1988-09-30
IE63874B1 (en) 1995-06-14
JPH04500966A (ja) 1992-02-20
AU4305189A (en) 1990-04-18
DK174523B1 (da) 2003-05-12
DK56291D0 (da) 1991-03-27
IE893123L (en) 1990-03-30
ATE86869T1 (de) 1993-04-15
JP2895896B2 (ja) 1999-05-24
PH26293A (en) 1992-04-10
EP0367735A1 (en) 1990-05-09
DE68905438D1 (de) 1993-04-22
PT91863A (pt) 1990-03-30
HU206988B (en) 1993-03-01
IL91796A (en) 1994-10-07
IL91796A0 (en) 1990-06-10
HUT57063A (en) 1991-11-28
HU895542D0 (en) 1991-10-28
WO1990003189A1 (en) 1990-04-05
EP0367735B1 (en) 1993-03-17
US5208019A (en) 1993-05-04
NZ230816A (en) 1997-06-24
CA1338722C (en) 1996-11-19
KR0137017B1 (ko) 1998-04-25
AU623181B2 (en) 1992-05-07
DE68905438T2 (de) 1993-09-30
PT91863B (pt) 1995-05-31
DK56291A (da) 1991-05-24
SE462364B (sv) 1990-06-18
KR900701308A (ko) 1990-12-01
SE8803472A (da) 1988-09-30

Similar Documents

Publication Publication Date Title
DD288094A5 (de) Verwendung von gamma-interferon zur behandlung von gefaessverengungen
DE69432179T3 (de) Eine formulierung des gerinnungsfaktors viii
AT408720B (de) Parenterale pharmazeutische formulierung eines humaninsulinanalogon-komplexes
DE10234192B4 (de) Verwendung von Erythropoetin
DE69433478T2 (de) Verwendung von stickoxid-addukten zur verhütung von thrombosen auf artifiziellen und vaskulären oberflächen
EP0508194A1 (de) Stabilisierte Faktor VIII-Präparationen
DE60029340T2 (de) Pharmazeutische zusammenstellungen enthaltend einen p2t rezeptor antagonist und melagatran
DE19857609A1 (de) Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
DE60037816T2 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
LU84546A1 (de) Verwendung von peptiden als medikamente
DE3937607A1 (de) Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
EP0586909A2 (de) Verwendung von C1-Inaktivator zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie des Capillary Leak Syndroms und Kreislaufschocks
EP0363671B1 (de) Verwendung von ACE-Inhibitoren gegen Neointimabildung nach Gefässverletzung
DE60128399T2 (de) Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen
DE60130906T2 (de) Synergistische wirkungen von hgf und antibakterieller behandlung
DE60301862T2 (de) Kombinationsbehandlung bei akutem myokardinfarkt
DE69836830T2 (de) Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten
EP0331014A2 (de) Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe
DE4115453A1 (de) Neue wirkstoffkombination
DE69530084T2 (de) Methode zur verminderung arterieller stenose
Vuopala et al. Dimethyl Sulfoxide (DMSO) Ointment in the Treatment of Rheumatoid Arthritis: A Double Blind Study
EP1528922B1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
DE69928539T2 (de) Zielrichtung und verlängerte assoziation von wirkstoffen an die luminale oberfläche der pulmonaren vaskularen endothelzellen
EP0411395A2 (de) Verwendung von ACE-Inhibitoren für die Atheroskleroseprophylaxe
AT407485B (de) Neue medizinische verwendung von alpha1-saurem glykoprotein

Legal Events

Date Code Title Description
RPI Change in the person, name or address of the patentee (searches according to art. 11 and 12 extension act)
RPV Change in the person, the name or the address of the representative (searches according to art. 11 and 12 extension act)
ASS Change of applicant or owner

Owner name: GENENTECH, INC., SOUTH SAN FRANCISCO, CA 94080

Effective date: 19941010

Owner name: JONASSON, LENA

Effective date: 19941010

Owner name: HOLM, JAN

Effective date: 19941010

IF04 In force in the year 2004

Expiry date: 20090929